Sells ultrasound wound-treatment systems and single-use applicators to hospitals, clinics, and other wound-care providers.
10-K for FY2025, filed Mar 26, 2026Our focus is regenerative medicine utilizing noninvasive ultrasound to produce a biological response promoting the repair and regeneration…View ↗
The Company develops and markets directed energy products that utilize ultrasound technology. UltraMIST is the only commercial product…View ↗
The UltraMIST system is highly portable and is used in hospitals, physician’s offices, wound centers, nursing homes, skilled nursing…View ↗
The Company sells systems through a combination of direct sales representatives, independent distributors, and resellers. The systems are…View ↗
Customers buy systems, consumables, parts, and accessories when goods ship. The company also earns extended-warranty and rental revenue over their terms, license fees under agreement terms, and repair revenue when work is performed.
10-K for FY2025, filed Mar 26, 2026System Sales, Consumables, Parts, and Accessories Sales - Systems, consumables, parts, and accessories sales include devices (new and…View ↗
Extended Warranty - The Company allocates the transaction price to the extended warranty based on standalone selling price. Warranty…View ↗
Licensing Fees - Licensing transactions include distribution licenses and intellectual property licenses. Licensing revenue is recognized…View ↗
Other Revenue - Other revenue primarily includes rentals, repairs, and billed freight. The Company recognizes rental revenue ratably over…View ↗
10-K for FY2025, filed Mar 26, 2026
FY2025 revenue by product or service ↗$44.1M
10-K for FY2025, filed Mar 26, 2026
$44.1M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Consumables, parts, and accessories revenue
Sold outright
10-K for FY2025, filed Mar 26, 2026 |
59% |
Consumables, parts, and accessories revenue, FY2025
$25.8M Sources
|
Sold outright |
|
System revenue
Sold outright
10-K for FY2025, filed Mar 26, 2026 |
41%
FY2022: 34%
|
System revenue, FY2025
$17.8M Sources
|
Sold outright |
|
Extended warranty
Recurring
|
0.4% |
Extended warranty, FY2025
$172K Sources
|
Recurring |
|
License fees
Licensed
|
0.1% |
License fees, FY2025
$20K Sources
|
Licensed |
|
Other
Mix
|
0.5% |
Other, FY2025
$206K Sources
|
Mix |
Hospitals, clinics, and other care facilities, as well as mobile wound-care providers, use its systems; sales go through Sanuwave's direct representatives, independent distributors, and resellers.
10-K for FY2025, filed Mar 26, 2026
Yes. It kept 27 cents of every revenue dollar as net income in FY2025 and turned 4 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 10, 2026
−$1.4MView ↗
8-K, filed Sep 25, 2026
In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company is provided a compliance period of 180 calendar days from the date of the…View ↗
8-K, filed Jun 16, 2026
Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 millionView ↗
Growing. Revenue grew 3.4x in 4 years, from $13M in FY2021 to $44.1M in FY2025, about 36% a year.
PACE product line exited
The older report named both UltraMIST and PACE as systems for continued commercialization; the latest report says PACE was sold and disposed of and identifies UltraMIST as its only commercial product.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026The continuation of our business is dependent upon raising additional capital. We expect to devote substantial resources for the expansion…View ↗
Competes with Solventum, Smith & Nephew, Molnlycke Health Care, Essity, Coloplast, Convatec, Organogenesis, MiMedx Group, Integra LifeSciences, Vericel, Kerecis, Arobella Medical, NanoVibronix, SoftWave Tissue Regeneration Technologies, MolecuLight, and MIMOSA Diagnostics
10-K for FY2025, filed Mar 26, 2026Major participants in the wound care market include multinational medical device and wound care companies such as Solventum, Smith &…View ↗
Loading...